MARKET

MRUS

MRUS

Merus
NASDAQ
47.45
+0.18
+0.38%
After Hours: 47.45 0 0.00% 16:00 02/23 EST
OPEN
47.50
PREV CLOSE
47.27
HIGH
47.99
LOW
46.26
VOLUME
506.52K
TURNOVER
0
52 WEEK HIGH
47.99
52 WEEK LOW
17.15
MARKET CAP
2.74B
P/E (TTM)
-12.7633
1D
5D
1M
3M
1Y
5Y
MRUS Crosses Above Average Analyst Target
NASDAQ · 6d ago
Weekly Report: what happened at MRUS last week (0212-0216)?
Weekly Report · 6d ago
Weekly Report: what happened at MRUS last week (0205-0209)?
Weekly Report · 02/12 11:53
Buy Rating on Merus Stock Amid Anticipated Phase 3 Trial and Promising Treatment Efficacy for HNSCC
TipRanks · 02/08 11:55
Weekly Report: what happened at MRUS last week (0129-0202)?
Weekly Report · 02/05 12:05
Investors growing more bullish on SMID cap biotech stocks
Investors growing more bullish on SMID cap biotech stocks. Merus and Fusion viewed as most likely to outperform the broader market this year. Investors are bullish on small caps and warming up to mid-caps, according to a TD Cowen investor sentiment survey. The IPO market is also expected to warm up.
Seeking Alpha · 02/04 22:16
Weekly Report: what happened at MRUS last week (0122-0126)?
Weekly Report · 01/29 11:49
Merus Stock: Rally Seems Overdone
Merus N.V. Shares have remained strong despite negative safety news about its MCLA-129 program. The company is focused on the development of bispecific cancer therapy candidates. Merus has a strong balance sheet and is expected to file for a BLA in mid-2024 for two promising candidates. Analyst firms have a median price target objective of $46 a share.
Seeking Alpha · 01/23 22:10
More
About MRUS
Merus NV is the Netherlands - based biotechnology company, concentrated on developing differentiating therapeutics for cancer patients. The product programs in the Merus pipeline are based on the Multiclonics format. Its products are designed to bind to multiple targets, and are manufactured with features for anti-cancer effects against the complex mechanisms that drive cancer. Company's products engage cancer antigens and harness the power of the immune system to kill tumor cells by utilizing technology platform. One of the drug zenocutuzumab (Zeno), a Biclonics antibody, concentrates on helping patients with lung, pancreatic and other types of solid tumors. The company operates in the Netherlands and United States.

Webull offers Merus NV stock information, including NASDAQ: MRUS real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, MRUS stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading MRUS stock methods without spending real money on the virtual paper trading platform.